🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Huge congratulations to Heather Robertson our Manager, Investor Relations & Corporate Communications who won the Best AScX (Euronext Amsterdam Small Cap index) Professional award last night at the Netherlands Association for Investor Relations Awards (#NEVIR). #Pharmingroup

We are delighted to have been shortlisted in two categories for the Citeline Scrip Awards 2023 for ‘Biotech Company of the Year award' and 'Best New Drug award'! For more information visit: bit.ly/3rrN2BO #shortlist #biopharma #ScripAwards

Join us live today at 14:00 CEST for our 2023 Extraordinary General Meeting of Shareholders. To watch the live feed, please click below. bit.ly/4648tb8 #EGM2023 #pharminggroup

Pharming Group NV reports on the results of the 2023 Extraordinary General Meeting of Shareholders and welcomes Dr. Richard Peters. Please click on the link below to read the press release in full. bit.ly/3tbzcEs #EGM2023 #pharminggroup

Pharming Group NV will report its 3Q 2023 financial results on Thursday, October 26, 2023, at 07:00 CEST. We will hold our conference call and webcast at 13:30 CEST/07:30 EDT. Please click on the link for info: bit.ly/3ZQ06xI #3Q23 #pharminggroup #financialresults

This morning Pharming Group NV published its third quarter 2023 financial results. To read the press release please click here: bit.ly/3SeR1N7 Management will hold an analyst & investor call today October 26 at 13:30 CEST/07:30 EDT #3Q23 #financialresults #pharminggroup

We are happy to share that Pharming Group NV management will participate in the #Jefferies London Healthcare Conference in the month of November. bit.ly/46OM2XY To schedule a meeting with management, reach out to [email protected] #jefferieshealthcare #pharminggroup

We are attending the International Primary Immunodeficiencies Congress (IPIC) 2023 taking place November 8-10 in Rotterdam, The Netherlands. The Pharming Team looks forward to seeing you at booth 16/17. To find out more about the congress, visit: ipic2023.com #IPIC2023

Pharming Group NV is pleased to welcome Daniela Dos Anjos Hanova as our new Chief People Officer (CPO) and member of the Executive Committee as of today. For more information please visit our website: bit.ly/3MthLpm

Tomorrow our CEO, Sijmen De Vries, will present at the Jefferies London Healthcare Conference at 08:30 GMT/09:30 CET. #jefferieshealthcare #conferences2023 #biopharma #pharminggroup

The first patient has been dosed in a Phase III pediatric clinical trial evaluating a new oral formulation of our PI3K delta inhibitor in children 1 to 6 years of age who have APDS. Learn more at bit.ly/3MUHlUN #pharminggroup

Wishing all who celebrate, a Happy Thanksgiving!

Wishing all who celebrate, a Happy Hanukkah!

For investors and medical media: Today, Pharming Group NV announces expansion of its rare disease pipeline with plans to develop its PI3K delta inhibitor for additional (PIDs) with immune dysregulation linked to PI3Kẟ signaling. bit.ly/3GHiP5M #pharminggroup #APDS #PID

Wishing all who celebrate, a Merry Christmas!

Read the interview between Kristie and Tyler and learn more about Tyler’s journey living with #APDS on Behind the Mystery, part of The Balancing Act -a LifeTimeTV program- devoted to advocating for rare and genetic diseases. bit.ly/47gnbfh #raredisease #pharminggroup

From all of us at Pharming, wishing you a Happy New Year and a great start to 2024!

The Pharming Group NV management team is in San Francisco this week. Contact [email protected] or [email protected] to schedule a meeting. #JPM2024

For Investors and Media: today, Pharming Group NV announces updated full year 2023 guidance and U.S. launch update bit.ly/3TRArDT

We are happy to share that Pharming Group NV management will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the UBS European Healthcare Conference in the month of February. bit.ly/3HOwHf0 #conference2024 #biopharma #pharminggroup